In den verfgbaren klinischen Daten wurden keine Hinweise auf schwerwiegende kardiovaskulre, hepatische oder systemische unerwnschte Wirkungen beobachtet, was Melanotan I von weniger selektiven Melanocortin-Agonisten unterscheidet
doi:10.2903/j.efsa.2017.4919
doi: 10.1089/omi.2011.0118 28 ZhouYZhouBPacheLChangMKhodabakhshiAHTanaseichukOet al
This observation may explain why semaglutide and other GLP-1 RAs ranked among the lowest-impact DM2 DMTs in our model compared to drugs such as metformin, which engage a broader range of metabolic and neuroprotective pathways (e.g., AMPK, insulin, and adipocytokine signaling)
Natasha Bhuyan, One Medicals national medical director and vice president of in-office care, spoke to The Healthy about the efficacy of GLP-1 patches, saying, None of these supplements have any evidence that they can help with weight loss. A new PBS report also noted that the studies Kind Patches referenced to support the use of berberine, glutamine, and chromium for weight loss were insufficient
& Milman, S